Brief: Generation Bio Announces Plan To Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio

Generation Bio

14/07/2021 12:36

July 14 (Reuters) - Generation Bio Co  GBIO.O :
    * GENERATION BIO ANNOUNCES PLAN TO SCALE NEXT-GENERATION
RAPID
ENZYMATIC MANUFACTURING PROCESS ACROSS PORTFOLIO AND PROVIDES
PIPELINE UPDATE
    * GENERATION BIO CO - IND SUBMISSION FOR HEMOPHILIA A NOW
PLANNED
FOR 2023
    * GENERATION BIO CO - FACTOR VIII EXPRESSION DATA WITH RES
MATERIAL IN NON-HUMAN PRIMATES EXPECTED YEAR-END 2021
    * GENERATION BIO CO - LEASE AGREEMENT SIGNED TO BUILD AN
IN-HOUSE
RES MANUFACTURING FACILITY PROVIDING CGMP CAPACITY
    * GENERATION BIO CO - FACILITY IS EXPECTED TO BE OPERATIONAL
IN
2023
    * GENERATION BIO CO - EXPENDITURES ON NEW FACILITY NOT
EXPECTED TO
IMPACT CO'S CASH RUNWAY, WHICH IS SUFFICIENT TO FUND KEY
MILESTONES INTO 2024
    * GENERATION BIO - ANTICIPATES INCURRING NET LEASE COSTS OF
$104
MILLION OVER A 12-YEAR PERIOD, INVESTING UP TO $45 MILLION IN
NEW FACILITY OVER NEXT TWO YEARS

Source text for Eikon:  ID:nGNX3dlMP2 
Further company coverage:  GBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))